title: Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide.
abstract: From December 1986 to April 1990, 40 consecutive ovarian cancer patients who relapsed after response to cisplatin-based chemotherapy regimens were treated with seven courses of weekly cisplatin, in combination with epirubicin or etoposide. The overall response rate obtained with the intensive schedule was 60% and the complete response rate was 25%; median duration of response was 7 months and median survival time, 13.5 months. Responsive cases seem to have longer survival; a prognostic factor for response to salvage treatment and longer survival is the disease-free interval after the first-line chemotherapy. Weekly cisplatin as intensive treatment was very well tolerated and showed acceptable toxicity in both the combination protocols with epirubicin or etoposide.
authors.affiliation: Department of Obstetrics and Gynecology, University of Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Zanaboni
authors.forename: G
authors.initials: G
authors.lastname: Scarfone
authors.forename: M
authors.initials: M
authors.lastname: Presti
authors.forename: R
authors.initials: R
authors.lastname: Maggi
authors.forename: C
authors.initials: C
authors.lastname: Borello
authors.forename: G
authors.initials: G
authors.lastname: Bolis
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012008:Recurrence
chemical_list: D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin